Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial

By sjmartinez • May 17, 2024

Liu JF, Gaillard S, Wahner Hendrickson AE, Yeku O, Diver E, Gunderson Jackson C, Arend R, Ratner E, Samnotra V, Gupta D, Chung J, Zhang H, Compton N, Baines A, Bacqué E, Liu X, Felicetti B, Konecny GE. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO Precis Oncol. 2024 May;8:e2300693. doi: 10.1200/PO.23.00693. PMID: 38754056.

Tags: Hematology/Oncology, Publications

Cullin-5 RING E3 ligase limits CD8⁺ T-cell persistence and effector responses during chronic antigen stimulation

Saco JD, Karin D, Patten JJ, Bachl S, Ching C, Kale N, Fan Y, Medina E, Naser Al Deen N, Champhekar A, Kaelin WG, Schulman[...]

Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance

Nishimura RN, Gera JF. Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance. Int J Mol Sci. 2026 Sep[...]

Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer

Tsimberidou AM, Cabanski CR, Drakaki A, Khalil DN, Siddiqui BA, Basu S, Okrah K, Da Silva DM, Gautam S, Alayli FA, Schachter M, Fairchild J,[...]